OOIR: Observatory of International Research

Papers

(The H4-Index of Dermatology and Therapy is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Adverse-Event Reports in Over-the-Counter Topical Acne Drug Products Containing Benzoyl Peroxide from a Specific Pharmaceutical Company in the USA	193
Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis	157
Hair Shaft Abnormalities as a Dermoscopic Feature of Mycosis Fungoides: Pilot Results	105
Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children	87
Enhanced Postablative Laser Skin Healing with a Regenerative Skincare Formulation: a Comparative Randomized Evaluator-Blinded Clinical Study	79
Management of Hidradenitis Suppurativa in the United Arab Emirates (UAE): A Consensus Statement from the Emirates Dermatology Society	75
Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD Registry	55
Pediatric Psychodermatology: Advancing Therapy through Integrated Care	55
Podcast: Adherence to Injectables	54
Pathological Insights into the Limitations of Clinical and Dermoscopic Evaluations in Monitoring Sonidegib Treatment Response for Locally Advanced Basal Cell Carcinoma: A Real-World Study	52
Sexual Dysfunction in Chronic Urticaria: A Systematic Review	51
Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study	50
Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry	49
Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals	48
Emerging Systemic Treatments for Atopic Dermatitis	44
Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence	41
Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review	40
Application of Comfort Therapy under eCASH Concept in Acute and Chronic Wound Treatment	38
The Impact of Step Therapy on Individuals with Psoriatic Disease in the USA: Patient and Provider Perspectives	38
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study	38
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis	37
Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies	37
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials	36
Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks	35
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis	35

Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives	34
Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments	33
Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis	33
A Pilot Study of Differences in Antibody Responses of Intradermal and Intramuscular Injections of Botulinum Toxin Type A	32
Successful Treatment of Severe Pemphigus Vulgaris with Reduced Side Effects Using a Novel IVIg Preparation	32
Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis	31
Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study	31
Chlormethine Gel for Treatment of Patients with Mycosis Fungoides: Best Practices and Guidance to Clinicians	31